Experienced in Atherosclerosis

Linda Aurpibul

Chiang Mai, TH 
Experienced in Atherosclerosis
Chiang Mai, TH 
OverviewLocationsClinical Research

Overview

Linda Aurpibul practices in Chiang Mai, Thailand. Ms. Aurpibul is rated as an Experienced expert by MediFind in the treatment of Atherosclerosis. Her top areas of expertise are HIV/AIDS, Japanese Encephalitis, Diphtheria, and Hepatitis B.

Her clinical research consists of co-authoring 88 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Atherosclerosis.

Gender
Female

Locations

Chiang Mai, Thailand

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age
Enrollment Status: Terminated
Publish Date: February 20, 2025
Intervention Type: Biological, Drug
Study Drug: RSV Maternal vaccine
Study Phase: Phase 3
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug
Study Drugs: Dolutegravir, ABC/DTG/3TC
Study Phase: Phase 3
An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg
An Open-label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-infected Adolescents, ≥12 to <18 Years of Age Who Weigh at Least 25 kg
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: Dolutegravir/Lamivudine
Study Phase: Phase 3
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
A Prospective Epidemiological Study of Pregnancy Outcomes and of Events of Interest in Pregnant Women, Neonates and Infants (PEPNI)
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Effect of Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among Perinatally HIV-infected Children and Adolescents
Effect of Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among Perinatally HIV-infected Children and Adolescents
Enrollment Status: Completed
Publish Date: August 08, 2019
Intervention Type: Dietary supplement
Study Phase: Phase 3
View 4 Less Clinical Trials

88 Total Publications

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.
Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands.
Journal: British journal of clinical pharmacology
Published: September 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Aurpibul's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile